clock.bio

Pre-clinical

London, United KingdomFounded 2021clock.bio

clock.bio is pioneering the field of rejuvenation biology, aiming to extend human healthspan by reversing cellular aging rather than just slowing it down. The company's integrated platform, comprising the geneAge Atlas, imAge AI model, and clinAge clinical trial engine, systematically maps genetic drivers of aging and validates interventions. Starting with topical and nutraceutical applications for rapid human validation, clock.bio is building a scientific foundation for future systemic therapies targeting the root causes of age-related decline.

Founded

2021

Focus

AI / Machine LearningDrug Discovery

AI Company Overview

Technology Platform

An integrated three-pillar platform comprising the geneAge Atlas (CRISPR-based map of the rejuvenation genome), imAge (AI-powered cellular age measurement from images), and clinAge (adaptive clinical trial engine) to systematically discover and validate interventions that reverse cellular aging.

Funding History

Total raised: $4M

Seed$4MUndisclosedMay 15, 2023

Opportunities

The primary growth opportunity lies in validating its rejuvenation platform with human data from topicals/nutraceuticals, which could unlock significant value through partnerships, licensing, or an IPO.

Successfully mapping the 'rejuvenation genome' could position clock.bio as a target discovery engine for the entire longevity industry.

The long-term opportunity is to develop first-in-class systemic therapies that reverse aging, addressing a multi-trillion-dollar burden of age-related disease.

Risk Factors

Key risks include the high scientific uncertainty of reversing human aging, the challenge of translating iPSC model findings into effective human therapies, intense competition in both longevity biotech and cosmeceuticals, and dependence on raising capital as a private, pre-revenue company in a sector subject to shifting investor sentiment.

Competitive Landscape

clock.bio competes with longevity biotechs like Unity Biotechnology and Altos Labs, as well as science-driven cosmeceutical companies. Its differentiation is its integrated platform focused explicitly on aging reversal (not slowing), its use of a proprietary human iPSC model for discovery, and its dual-path strategy of near-term revenue-generating products funding long-term systemic therapeutics.